Probatebeta
Target

CSF3R

Granulocyte colony-stimulating factor receptor

As of the edition of 20 October 2026, CSF3R (granulocyte colony-stimulating factor receptor, UniProt Q99062) has 12 drugs tested at it and 42 companies on the list, 20 on route A and 8 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q99062
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
1
Disease areas
Cancer; Blood and lymph; Immune system; Skin and connective tissue; Urinary and reproductive; Heart and blood vessels; Infections; Pregnancy and women's health
Registered trials of its drugs
1,413

Drugs at this target

StatusCount
Marketed7
Active1
Went quiet1
Stopped2
Status not established1
Total12
DrugStatusFurthest phaseUS protection
FilgrastimMarketedPhase 4Ended 2022
PegfilgrastimMarketedPhase 4Ended 2022
RegramostimStoppedPhase 4none listed
LenograstimMarketedPhase 4none listed
Efbemalenograstim alfaMarketedPhase 3Ends 2035
MolgramostimMarketedPhase 4none listed
EflapegrastimMarketedPhase 4Ends 2034
AnumigilimabActivePhase 2none listed
LipegfilgrastimMarketedPhase 3none listed
BalugrastimStoppedPhase 3none listed
PegteograstimStatus not establishedPhase 2none listed
DA-3031Went quietPhase 1none listed

12 of 12 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A20
Route B8
Engaged8
Undetermined6
Total on the list42
Three companies on route A or B, with the route only
CompanyRoute
Changchun GeneScience PharmaceuticalRoute A
PfizerRoute B
Eli LillyRoute A

The other 39 companies at CSF3R

In the product

42 companies in all; 39 are not named here, and no score is.

See the 42 companies at CSF3R, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

Other targets in cancer

Companies holding approvals at CSF3R